Drug intelligence / Profile preview

HY-078020

Development stage: Preclinical
Lead developer: Hefei Medical and Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

HY-078020 is a selective, orally active small molecule antagonist of the histamine H1 receptor. It demonstrates potent anti-inflammatory activity with an IC50 of 24.12 nM for the H1 receptor. The drug is being investigated primarily for its anti-inflammatory effects and potential use in allergic diseases[2][9]. Its mechanism of action involves blocking the histamine H1 receptor, thereby inhibiting histamine-mediated inflammatory responses.

Other names: HY-078020HY078020HY 078020compound III-4

Targets

HRH1 (Histamine H1 Receptor)CHRM3 (M3)KCNH2 (Voltage-gated potassium channel subfamily H member 2)

Beyond the preview

Go deeper on HY-078020.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HY-078020.

Explore the full profile